Cargando…

288. Expediting Discharge in Acute Bacterial Skin and Skin Structure Infections: A Clinical and Economic Comparison Between Vancomycin and Oritavancin

BACKGROUND: Acute bacterial skin and skin structure infections (ABSSSI) have a high economic burden secondary to prolonged hospitalizations and high rates of recurrent infections. Utilizing oritavancin rather than vancomycin, select inpatients may be discharged earlier in their hospitalization with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Whittaker, Cristen, Nhan, Ethan, Ganapathiraju, Pavan, Garrett, Sandra, Reilly, Joseph, Trivedi, Manish
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253589/ http://dx.doi.org/10.1093/ofid/ofy210.299

Ejemplares similares

447. Disease Progression in Patients with Acute Bacterial Skin and Skin Structure Infections: A Comparative Analysis Between Oritavancin and Vancomycin
por: Whittaker, Cristen A, et al.
Publicado: (2019)

Expediting Discharge in Hospitalized, Adult Patients with Skin and Soft Tissue Infections Who Received Empiric Vancomycin Therapy with Oritavancin: Description of Findings from an Institutional Pathway
por: Whittaker, Cristen, et al.
Publicado: (2020)

1555. Risk of Developing Acute Kidney Injury in Patients Receiving Piperacillin–Tazobactam and Vancomycin Compared with Those on Piperacillin–Tazobactam and Telavancin
por: Reilly, Joseph, et al.
Publicado: (2019)

Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review
por: Kmeid, Joumana, et al.
Publicado: (2015)

Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials
por: Lodise, Thomas P., et al.
Publicado: (2017)

59. Evaluation of Drug-Bug Mismatch Alerts and Their Value in an Antimicrobial Stewardship Program
por: Whittaker, Cristen A, et al.
Publicado: (2020)

Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections
por: Mitra, Subhashis, et al.
Publicado: (2015)

1331 The SOLO Studies: A Single-Dose of Oritavancin (ORI) Compared to 7-10 Days of Vancomycin (VAN) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
por: Corey, Ralph, et al.
Publicado: (2014)

Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital
por: Saddler, Kimberly, et al.
Publicado: (2021)

Evaluation of Dalbavancin and Oritavancin as Cost-Effective Treatments of Acute Bacterial Skin and Skin Structure Infections in Hospitalized Patients
por: Koutsari, Christina, et al.
Publicado: (2017)

Cost-minimisation analysis of oritavancin for the treatment of acute bacterial skin and skin structure infections from a United Kingdom perspective
por: Zinzi, Daniela, et al.
Publicado: (2022)

Prolonged Use of Oritavancin for Vancomycin-Resistant Enterococcus faecium Prosthetic Valve Endocarditis
por: Johnson, Jennifer A., et al.
Publicado: (2015)

Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting
por: Deck, Daniel H., et al.
Publicado: (2016)

In Vitro and In Vivo Studies of Oritavancin and Fosfomycin Synergism against Vancomycin-Resistant Enterococcus faecium
por: Lagatolla, Cristina, et al.
Publicado: (2022)

Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis
por: Jensen, Ivar S., et al.
Publicado: (2015)

Erratum to: Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting
por: Deck, Daniel H., et al.
Publicado: (2016)

Real-World Use of Oritavancin for the Treatment of Osteomyelitis
por: Scoble, Patrick J., et al.
Publicado: (2020)

Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who Were Treated With Oritavancin or Vancomycin for a Skin Infection in the Outpatient Setting
por: Lodise, Thomas P, et al.
Publicado: (2019)

Vibrational Optical Activity Study of Four Antibiotic (Lipo)glycopeptides: Vancomycin, Oritavancin, Dalbavancin, and Teicoplanin
por: Aerts, Roy, et al.
Publicado: (2022)

Single-Dose Oritavancin Compared to Standard of Care IV Antibiotics for Acute Bacterial Skin and Skin Structure Infection in the Outpatient Setting: A Retrospective Real-World Study
por: Anastasio, Patrick J., et al.
Publicado: (2017)

288 Lack of Synergy With Six Blood Isolates of Methicillin-Resistant Staphylococcus aureus (Vancomycin MIC of 2) Tested With Combinations of Vancomycin + Gentamicin, Vancomycin + Rifampin and Vancomycin + Cefazolin.
por: Long, Virginia, et al.
Publicado: (2014)

470 Oritavancin Activity Against Gram-positive Clinical Isolates Responsible for Documented Skin and Skin Structure Infections in USA and European Hospitals (2012-2013)
por: Mendes, Rodrigo E., et al.
Publicado: (2014)

The Real-World Economic and Clinical Management of Adult Patients with Skin and Soft Tissue Infections (SSTIs) with Oritavancin: Data from Two Multicenter Observational Cohort Studies
por: Estrada, Sandy, et al.
Publicado: (2020)

1928. Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who Were Treated With Oritavancin (ORI) or Vancomycin (VAN) for a Skin Infection in the Outpatient Setting
por: Lodise, Thomas, et al.
Publicado: (2018)

1811. Impact of a one-time oritavancin infusion on hospital length of stay for uncomplicated skin and soft tissue infections
por: Bremmer, Derek N, et al.
Publicado: (2023)

Early Directed Oritavancin Therapy in the Emergency Department May Lead to Hospital Avoidance Compared to Standard Treatment for Acute Bacterial Skin and Skin Structure Infections: A Real-World Retrospective Analysis
por: Helton, Brittany, et al.
Publicado: (2020)

Contents to volume 288
Publicado: (1991)

675 Outcomes of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) by vancomycin dosing regimen and vancomycin trough serum concentrations in the DISCOVER Program
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

1812. Comparative Activity of Oritavancin and Comparator Agents against Staphylococcus aureus and Streptococcus spp. Causing Skin and Skin Structure Infections in US Medical Centers between 2017–2019 and 2022
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

Impact of expedited discharge during the Coronavirus 2019 pandemic
por: Vani, Kavita, et al.
Publicado: (2022)

Author index to volume 288
Publicado: (1991)

1719. Pharmacokinetics (PK) of Oritavancin in Children: The ORKIDS Trial
por: Bradley, John, et al.
Publicado: (2018)

The Clinical Efficacy of Multidose Oritavancin: A Systematic Review
por: Baiardi, Giammarco, et al.
Publicado: (2023)

Ballade op. 288 : für Flöte und Klavier /
por: Reinecke, Carl

Post-Discharge Antibiotic Therapy in Patients with Acute Bacterial Skin and Skin Structure Infections
por: Caffrey, Aisling, et al.
Publicado: (2017)

Acute postpartum care utilization after expedited postpartum discharge
por: Panzer, Alexis, et al.
Publicado: (2022)

Health Tract, No. 288: Malaria and Miasm
Publicado: (1867)

1629. Vancomycin Resistance in Enterococcus faecium Clinical Isolates Responsible for Bloodstream Infections in US Hospitals Over Ten Years (2010-2019) and Activity of Oritavancin
por: Carvalhaes, Cecilia G, et al.
Publicado: (2020)

Oritavancin polymethylmethacrylate (PMMA)—compressive strength testing and in vitro elution
por: Schmidt-Malan, Suzannah M., et al.
Publicado: (2019)

Real-World Evidence for Oritavancin Use in Gram-Positive Infections
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ofs284stijjsuqu4oqlbiu22ud